ANDA 201963, held by Actavis Elizabeth. Pramipexole Dihydrochloride.
As of Nov 16, 2026, ANDA 201963 (Pramipexole Dihydrochloride), held by Actavis Elizabeth, was first approved by FDA on Apr 21, 2016, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2016 | Original application | Approved | None posted |
| Pramipexole Dihydrochloride0.375MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Pramipexole Dihydrochloride0.75MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Pramipexole Dihydrochloride1.5MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Pramipexole Dihydrochloride3MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Pramipexole Dihydrochloride4.5MG · tablet, extended release;oral | Pramipexole Dihydrochloride | Rx |
| Jun 16, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 15, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 15, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 15, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 21, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters